Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23291787 | 0.84 | CSNK1A1 (0.40) | CSNK1A1CLK4CYP11B2CYP11B1KMT2A | |
| SCHEMBL1920551 | 0.77 | CYP11B2 (0.40) | CSNK1A1CLK4CYP11B2CYP11B1KMT2A | |
| SCHEMBL21927175 | 0.76 | CYP11B1 (0.30) | CYP11B2CYP11B1 | |
| SCHEMBL7228049 | 0.75 | — | — | |
| SCHEMBL2931936 | 0.74 | CSNK1A1 (0.34) | CSNK1A1CLK4CYP11B2CYP11B1KMT2A | |
| SCHEMBL1215960 | 0.74 | CYP11B2 (0.45) | CYP11B2CYP11B1 | |
| SCHEMBL14157718 | 0.74 | ALDH1A1 (0.37) | CSNK1A1CLK4CYP11B2CYP11B1KMT2A | |
| SCHEMBL2931592 | 0.74 | TTR (0.40) | — | |
| SCHEMBL30551593 | 0.74 | TSHR (0.37) | CYP11B2CYP11B1ALDH1A1 | |
| SCHEMBL13223329 | 0.74 | TSHR (0.37) | CYP11B2CYP11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029543-B1 | SUBSTITUTED 3-CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH LLC (US) | 2015-11-18 | — | — | EP | disclosed |
| EP-2029543-B1 | SUBSTITUTED 3-CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH LLC (US) | 2015-11-18 | — | — | EP | disclosed |
| EP-2229377-A1 | 5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS | Wyeth LLC (US) | 2010-09-22 | — | — | EP | disclosed |
| US-7781591-B2 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781591-B2 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC (US) | 2010-08-24 | — | — | US | disclosed |
| WO-2009076602-A1 | 5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS | WYETH (US) | 2009-06-18 | — | — | WO | disclosed |
| EP-2029543-A2 | SUBSTITUTED 3-CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | Wyeth (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-2027093-A2 | SUBSTITUTED CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | Wyeth (US) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007146376-A2 | SUBSTITUTED 3-CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007146323-A2 | SUBSTITUTED CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC | 2007-12-13 | — | — | US | disclosed |
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC | 2007-12-13 | — | — | US | disclosed |
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC | 2007-12-13 | — | — | US | disclosed |
| US-20070287738-A1 | Substituted Cyanopyridines as protein kinase inhibitors | WYETH | 2007-12-13 | — | — | US | disclosed |
| US-20070287738-A1 | Substituted Cyanopyridines as protein kinase inhibitors | WYETH | 2007-12-13 | — | — | US | disclosed |
| US-20070287738-A1 | Substituted Cyanopyridines as protein kinase inhibitors | WYETH | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | CNKSR1, MAP3K1, MAP3K7 | CSNK1A1 26/4885CLK4 268/4885CYP11B2 2155/4885 |
| US-20070287738-A1 | Substituted Cyanopyridines as protein kinase inhibitors | CNKSR1, MAP3K1, MAP3K6 | CSNK1A1 17/4885CLK4 129/4885CYP11B2 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.